Kenneth R. Chien

Kenneth R. Chien

Auto-generated profile, based on publicly available information

Kenneth R. Chien

Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden.

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2022 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
EREduarde Rohner
Eduarde Rohner
RYRan Yang
Ran Yang
KFKylie S. Foo
Kylie S. Foo
AGAlexander Goedel
Alexander Goedel
KCKenneth R. Chien
Kenneth R. Chien
The extraordinary success of mRNA vaccines against coronavirus disease 2019 (COVID-19) has renewed interest in mRNA as a means of delivering therapeutic proteins. Early clinical trials of mRNA therapeutics include studies of paracrine vascular endothelial growth factor (VEGF) mRNA for heart failure and of CRISPR–Cas9 mRNA for a congenital liver-specific storage disease. However, a series of challenges remains to be addressed before mRNA can be established as a general therapeutic modality with broad relevance to both rare and common diseases. An array of new technologies is being developed to surmount these challenges, including approaches to optimize mRNA cargos, lipid carriers with inherent tissue tropism and in vivo percutaneous delivery systems. The judicious integration of these advances may unlock the promise of biologically targeted mRNA therapeutics, beyond vaccines and other immunostimulatory agents, for the treatment of diverse clinical indications.

8 September 2013 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
LZLior Zangi
Lior Zangi
KLKathy Lui
Kathy Lui
AGAlexander von Gise
Alexander von Gise
QMQing Ma
Qing Ma
WEWataru Ebina
Wataru Ebina
KCKenneth R Chien
Kenneth R Chien

1 June 2018 in Molecular Therapy - Methods & Clinical Development
Verified
Journal Article
Open access
LCLeif Carlsson
Leif Carlsson
JCJonathan C. Clarke
Jonathan C. Clarke
CYChristopher Yen
Christopher Yen
FGFrancine Gregoire
Francine Gregoire
TATamsin Albery
Tamsin Albery
RFRegina Fritsche-Danielson
Regina Fritsche-Danielson
MRNA can direct dose-dependent protein expression in cardiac muscle without genome integration, but to date has not been shown to improve cardiac function in a safe, clinically applicable way. Herein, we report that a purified and optimized mRNA in a biocompatible citrate-saline formulation is tissue specific, long acting, and does not stimulate an immune response. In small- and large-animal, permanent occlusion myocardial infarction models, VEGF-A 165 mRNA improves systolic ventricular function and limits myocardial damage. Following a single administration a week post-infarction in mini pigs, left ventricular ejection fraction, inotropy, and ventricular compliance improved, border zone arteriolar and capillary density increased, and myocardial fibrosis decreased at 2 months post-treatment. Purified VEGF-A mRNA establishes the feasibility of improving cardiac function in the sub-acute therapeutic window and may represent a new class of therapies for ischemic injury.

18 February 2019 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
KCKenneth R. Chien
Kenneth R. Chien
JFJonas Frisén
Jonas Frisén
RFRegina Fritsche-Danielson
Regina Fritsche-Danielson
DMDouglas A. Melton
Douglas A. Melton
CMCharles E. Murry
Charles E. Murry
IWIrving L. Weissman
Irving L. Weissman

1 December 2014 in Development
Verified
Journal Article
Open access
PDF file
DSDaniela Später
Daniela Später
EHEmil M. Hansson
Emil M. Hansson
LZLior Zangi
Lior Zangi
KCKenneth R. Chien
Kenneth R. Chien
During development, cardiogenesis is orchestrated by a family of heart progenitors that build distinct regions of the heart. Each region contains diverse cell types that assemble to form the complex structures of the individual cardiac compartments. Cardiomyocytes are the main cell type found in the heart and ensure contraction of the chambers and efficient blood flow throughout the body. Injury to the cardiac muscle often leads to heart failure due to the loss of a large number of cardiomyocytes and its limited intrinsic capacity to regenerate the damaged tissue, making it one of the leading causes of morbidity and mortality worldwide. In this Primer we discuss how insights into the molecular and cellular framework underlying cardiac development can be used to guide the in vitro specification of cardiomyocytes, whether by directed differentiation of pluripotent stem cells or via direct lineage conversion. Additional strategies to generate cardiomyocytes in situ, such as reactivation of endogenous cardiac progenitors and induction of cardiomyocyte proliferation, will also be discussed.

26 August 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
RYRan Yang
Ran Yang
AGAlexander Goedel
Alexander Goedel
YKYu Kang
Yu Kang
CSChenyang Si
Chenyang Si
CCChu Chu
Chu Chu
KCKenneth R. Chien
Kenneth R. Chien
Embryonic development is largely conserved among mammals. However, certain genes show divergent functions. By generating a transcriptional atlas containing >30,000 cells from post-implantation non-human primate embryos, we uncover that ISL1, a gene with a well-established role in cardiogenesis, controls a gene regulatory network in primate amnion. CRISPR/Cas9-targeting of ISL1 results in non-human primate embryos which do not yield viable offspring, demonstrating that ISL1 is critically required in primate embryogenesis. On a cellular level, mutant ISL1 embryos display a failure in mesoderm formation due to reduced BMP4 signaling from the amnion. Via loss of function and rescue studies in human embryonic stem cells we confirm a similar role of ISL1 in human in vitro derived amnion. This study highlights the importance of the amnion as a signaling center during primate mesoderm formation and demonstrates the potential of in vitro primate model systems to dissect the genetics of early human embryonic development.